Study population characteristics
|
Gender (proportion female) | 88/254* (34.6%) |
Mean age | 9.5 years (SD±5.2) |
Proportion of patients in each racial group |
African American | 118/254 (46.4%) |
White/Caucasian | 105/254 (41.3%) |
Other | 31/254 (12.2%) |
Prescription characteristics
|
Opioid prescribed (n, % of total) |
Oxycodone | 248 (96.1%) |
Hydromorphone | 2 (0.8%) |
Morphine | 1 (0.4%) |
Tramadol | 1 (0.4%) |
Combination product | 6 (2.3%) |
Number per age group (n, % of total) |
All ages | 258 |
0–2 years | 35 (13.6%) |
3–6 years | 44 (17%) |
7–12 years | 98 (38%) |
>12 years | 81 (31.4%) |
Doses per prescription (mean±SD) |
All ages | 14.7±9.1 |
0–2 years | 14.0±7 |
3–6 years | 14.0±8.3 |
7–12 years | 16.7±10.8 |
>12 years | 13.0±7.5 |
Number of liquid formulation (n, % of total) |
All ages | 133, 51.6% |
0–2 years | 34, 97.1% |
3–6 years | 43, 97.7% |
7–12 years | 51, 52% |
>12 years | 5, 6.2% |
Prescription error | 3, 1.2% |
Prescriber characteristics
|
Number of prescriptions per prescriber group |
Resident | 189 |
PGY1 | 71 |
PGY2 | 70 |
PGY3+ | 48 |
Non-resident | 69 |
Number of doses per prescription (mean±SD) |
Resident | 15.6±9.5† |
PGY1 | 13.9±8.3 |
PGY2 | 18.4±11.6 |
PGY3+ | 14.0±6.8 |
Non-resident | 12.2±7.4† |